MRNA

Moderna, Inc. 2025 Q2 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Moderna, Inc. is a biotechnology company developing mRNA medicines across respiratory virus vaccines, oncology therapeutics, and rare disease therapeutics. The company currently has three commercial products: Spikevax (COVID-19), mRESVIA (RSV), and mNEXSPIKE (next-generation COVID-19). As of the reporting date, mNEXSPIKE had received FDA approval but had not yet launched commercial sales.

Key Financial Metrics

Note: Cost of sales for Q2 2025 was $119 million, exceeding net product sales due to inventory write-downs ($38 million) and unutilized manufacturing capacity costs ($52 million).

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 41% year-over-year in Q2 2025. Net product sales fell 38% to $114 million, driven by lower U.S. sales volume and reduced average selling prices as the COVID market transitions to a seasonal model.
• Expense Reductions: Research and development (R&D) expenses dropped 43% to $700 million, and Selling, General, and Administrative (SG&A) expenses fell 14% to $230 million. These reductions reflect disciplined cost management, portfolio prioritization, and lower headcount.
• Improved Loss Profile: Despite lower revenue, the net loss narrowed significantly by 35% to $825 million, primarily due to the substantial decrease in operating expenses.
• Inventory Build-up: Inventory increased to $240 million (from $117 million at year-end 2024) as the company prepared for the upcoming respiratory season, though this included $80 million in write-downs for the six-month period.

Guidance, Outlook, and Risks

• Product Pipeline:
  • mNEXSPIKE: Approved in May 2025 for adults 65+ and at-risk individuals 12-64. Commercial launch expected for the 2025-2026 respiratory season.
  • mRESVIA: FDA approval expanded in June 2025 to include adults aged 18-59 with underlying conditions.
  • Seasonal Flu: Phase 3 results for mRNA-1010 showed superior efficacy (26.6% relative vaccine efficacy) compared to standard vaccines. Filing for FDA approval is in preparation.
• Funding & Grants: The BARDA contract for the original COVID vaccine concluded in June 2025. A separate award for pandemic influenza vaccine development was terminated in May 2025, though interim data remains positive.
• Liquidity: The company holds $7.5 billion in cash and investments. Management believes these resources are sufficient to fund operations for at least the next 12 months.
• Risks:
  • Legal Proceedings: Ongoing patent litigation with Pfizer, BioNTech, Alnylam, Arbutus, and GSK regarding mRNA platform and lipid nanoparticle technologies.
  • Market Dynamics: Continued decline in COVID vaccination rates and increased competition in the respiratory vaccine market.
  • Manufacturing Costs: High fixed costs and inventory write-downs due to demand forecast adjustments.

Investor Verification Checklist

• Commercial Launch Timing: Verify the specific launch date and initial sales projections for mNEXSPIKE, which is approved but not yet generating revenue.
• Inventory Valuation: Assess the risk of further inventory write-downs given the $80 million charge in the first half of 2025 and the transition to seasonal demand.
• Legal Exposure: Monitor the status of patent litigation, particularly the trial rescheduled for March 2026 against Arbutus/Genevant and new UPC lawsuits filed by GSK.
• Flu Vaccine Approval: Track the FDA review timeline for the seasonal flu vaccine (mRNA-1010) following the positive Phase 3 data.
• Cash Burn Rate: Evaluate the sustainability of the current operating cash burn (~$2 billion per six months) against the $7.5 billion cash balance.